MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$55,477K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from convertible notes,...
Proceeds from maturities of inve...
Loss on debt extinguishment
Others
Negative Cash Flow Breakdown
Purchases of investments
Repayment of note payable
Net loss
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-78,864
-52,841
-50,973
-43,804
Depreciation
59
47
49
41
Stock-based compensation
6,904
5,325
9,456
6,779
Amortization of debt issuance costs and discount
1,214
1,252
1,271
778
Payment-in-kind interest
257
325
331
272
Non-cash investment (income) expense
-332
883
-
-
Non-cash operating lease expense
65
-3
-2
-5
Change in accrued interest income
-
-
-1,470
1,180
Loss on debt extinguishment
-11,477
-
-
-
Prepaid clinical trial costs
-2,378
-3,522
12,127
-
Other current assets
2,579
976
-7,709
5,449
Accounts payable
-2,276
4,080
-4,825
-55
Accrued clinical trial costs
-829
-8,055
118
-
Accrued license milestone
5,000
-
-
-
Accrued expenses
-
-
-
-2,195
Other accrued expenses
11,436
-6,858
15,388
-
Net cash used in operating activities
-55,426
-55,065
-36,399
-44,816
Proceeds from maturities of investments
115,000
50,000
103,462
32,307
Purchases of investments
445,454
15,196
0
289,821
Purchases of property and equipment
51
249
53
97
Purchases of capitalized software
85
36
-
-
Net cash provided by (used in) investing activities
-330,590
34,519
103,409
-257,611
Proceeds from employee stock purchases
798
-
458
0
Proceeds from note payable, net of debt issuance costs of 2,255 and 2,438 during the years ended december 31, 2025 and 2024, respectively
-
-
-7
27,752
Proceeds from exercise of common stock options
1,677
206
1,101
2,364
Proceeds from equity offering, net of underwriting discounts and offering costs
-
-
-231
91,823
Proceeds from exercise of common stock warrants
0
31
23,591
12,870
Proceeds from convertible notes, net of debt issuance costs of 17,584 and 0 during the six months ended june 30, 2026 and 2025, respectively
557,416
-
-472
195,476
Repayment of note payable
137,017
-
-
-
Payments for secondary registration statement costs
0
203
-1
47
Net cash provided by financing activities
422,874
34
24,441
330,325
Net change in cash and cash equivalents
36,858
-20,512
91,451
27,898
Beginning of period
145,191
165,703
74,252
22,515
End of period
182,049
145,191
165,703
74,252
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from
convertible notes, net of...
$557,416K
Proceeds from exercise of
common stock options
$1,677K
(8285.00%↑ Y/Y)
Proceeds from employee
stock purchases
$798K
(215.42%↑ Y/Y)
Net cash provided by
financing activities
$422,874K
(7208.57%↑ Y/Y)
Canceled cashflow
$137,017K
Net change in cash
and cash...
$36,858K
(54.61%↑ Y/Y)
Canceled cashflow
$386,016K
Repayment of note payable
$137,017K
Proceeds from maturities
of investments
$115,000K
(-41.55%↓ Y/Y)
Loss on debt
extinguishment
-$11,477K
Other accrued
expenses
$11,436K
Stock-based compensation
$6,904K
(34.11%↑ Y/Y)
Prepaid clinical trial
costs
-$2,378K
Amortization of debt issuance
costs and discount
$1,214K
(11.58%↑ Y/Y)
Non-cash investment
(income) expense
-$332K
Payment-in-kind interest
$257K
(-48.70%↓ Y/Y)
Non-cash operating lease
expense
$65K
Depreciation
$59K
(-23.38%↓ Y/Y)
Net cash provided by
(used in) investing...
-$330,590K
(-466.84%↓ Y/Y)
Net cash used in
operating activities
-$55,426K
(23.09%↑ Y/Y)
Canceled cashflow
$115,000K
Canceled cashflow
$34,122K
Purchases of investments
$445,454K
(318.18%↑ Y/Y)
Net loss
-$78,864K
(4.13%↑ Y/Y)
Purchases of capitalized
software
$85K
Purchases of property and
equipment
$51K
(-48.48%↓ Y/Y)
Accrued license
milestone
$5,000K
Other current assets
$2,579K
(-50.89%↓ Y/Y)
Accounts payable
-$2,276K
(-223.70%↓ Y/Y)
Accrued clinical trial
costs
-$829K
Buy us a coffee
Celcuity Inc. (CELC)
Celcuity Inc. (CELC)